A total of 60 clinical strains were tested in this study: 30 each for K. pneumoniae and P. aeruginosa. All clinical isolates were isolated from clinical specimens, such as urine, secretions, and blood, recovered from two tertiary care hospitals in Cali, Colombia, between 2017 and 2019. All cultures of clinical isolates were sent to Microbiology Laboratory at Laboratorio de Salud Pública Departamental del Valle del Cauca (LSPD-Valle), where bacterial identity was confirmed, and antibiotic susceptibility characterization was performed. Species identification was performed using the automated VITEK® 2 system, (bioMerieux, 9.02, Marcy l’Etoile, France) with the VITEK® 2 Gram-Negative Identification card (VITEK® 2 GN ID), which is based on established biochemical methods and substrates that evaluate the use of carbon, enzymatic activity, and resistance (Ref. 21341, bioMerieux, Marcy l’Etoile, France). All laboratory strains, including E. coli ATCC® 25922™, K. pneumoniae ATCC® 2146™, and P. aeruginosa ATCC® 27853™, were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).
Rivera-Sánchez S.P., Agudelo-Góngora H.A., Oñate-Garzón J., Flórez-Elvira L.J., Correa A., Londoño P.A., Londoño-Mosquera J.D., Aragón-Muriel A., Polo-Cerón D, & Ocampo-Ibáñez I.D. (2020). Antibacterial Activity of a Cationic Antimicrobial Peptide against Multidrug-Resistant Gram-Negative Clinical Isolates and Their Potential Molecular Targets. Molecules, 25(21), 5035.